Form 8-K - Current report:
SEC Accession No. 0000950170-25-027717
Filing Date
2025-02-26
Accepted
2025-02-26 16:05:37
Documents
12
Period of Report
2025-02-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K srpt-20250226.htm   iXBRL 8-K 45990
2 EX-99.1 srpt-ex99_1.htm EX-99.1 829878
  Complete submission text file 0000950170-25-027717.txt   1028947

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT srpt-20250226.xsd EX-101.SCH 23883
14 EXTRACTED XBRL INSTANCE DOCUMENT srpt-20250226_htm.xml XML 4527
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Filer) CIK: 0000873303 (see all company filings)

EIN.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14895 | Film No.: 25669963
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)